NY-DILIGENT/INSIGHTIA
11.1.2022 14:02:12 CET | Business Wire | Press release
Diligent , the global leader in modern governance providing SaaS solutions across governance, risk, compliance and ESG, today announced that it has acquired Insightia, a leading SaaS provider of expert insights and intelligent analytics for listed companies, with a focus on shareholder activism, proxy voting and corporate governance. Financial terms of the transaction were not disclosed.
Formed from the 2020 merger of Activist Insight and Proxy Insight, Insightia offers a single source of global public company information to a range of global investment banks, law firms, proxy solicitors, and other corporate advisors. Representative clients include PJT CamberView, Glass Lewis, Morrow Sodali, FTI Consulting, and Georgeson.
Bringing together Diligent’s leading governance, analytics and ESG solutions with Insightia’s vital intelligence across a variety of public company data will provide clients with even more meaningful insights to power their board and organizations’ governance practices. Clients will have access to a rich ecosystem of organizational risk assessments and data tools in areas spanning board composition, executive compensation, supply chain due diligence, and ESG standards and frameworks. Diligent will also pursue a range of potential solution integrations with Insightia, including adding activist investor alerts within its Boards application, enabling clients to better monitor susceptibility to activism.
Brian Stafford, CEO of Diligent, said: “From our regular interactions with board members, business leaders and investors, we understand that having access to the most comprehensive and relevant data facilitates better guidance and confident decision-making. That is why we are so pleased to bring onboard Insightia’s deep experience and market-leading intelligent analytics, particularly against the backdrop of a marketplace where shareholder engagement is rapidly evolving. Current and future clients can look forward to even more insights on the issues that matter most so that they can continue to build successful, equitable and sustainable organizations.”
Kerry Pogue, Co-Founder and CEO of Insightia, said: “We are excited to benefit from Diligent’s expertise and resources as a leading SaaS organization in this next phase of Insightia’s growth journey. Combining our capabilities with Diligent’s governance, analytics and ESG solutions is a compelling next step as we look to scale our offerings globally for the benefit of our clients. Both companies are incredibly complementary in terms of their strategy and culture, and our team looks forward to being part of Diligent and accelerating the reach of our mission.”
District Capital Partners served as the exclusive financial advisor, and Willkie Farr & Gallagher LLP served as the legal advisor to Diligent. Taylor Wessing served as the legal advisor to Insightia.
About Diligent Corporation
Diligent is the global leader in modern governance providing SaaS solutions across governance, risk, compliance and ESG to over 1 million users from over 25,000 customers around the world. Our innovative technology gives leaders a connected view of governance, risk, compliance and ESG across their organizations, sparking the insights they need to make better decisions and lead with purpose. Learn more at diligent.com .
About Insightia
Headquartered in London, Insightia was formed in 2020 through the merger of Activist Insight and Proxy Insight, who together have provided a variety of shareholder activism, shareholder voting, and corporate governance data to a global client base for the past decade. Insightia’s mission is to improve engagement, stewardship and corporate governance through the delivery of timely intelligence to key stakeholders and their advisors. Learn more at insightia.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005384/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
